sec filing
NM
NASDAQ · NMRA
Neumora Therapeutics, Inc. Common Stock
Healthcare · Biotechnology
$0.77
Down-$0.02 (-3.00%)
Updated Sep 17, 2026, 10:53 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 346.56M
- P/E ratio
- -1.42
- Dividend yield
- 0.00%
- 52-week range
- $0.76 – $3.52
- Volume
- 3.22M
- Avg. volume
- 1.61M
Price performance
NMRA price history
1M range · 20 trading sessions · Daily adjusted prices
NMRA closed at $0.77 after 20 trading sessions, down 52.85% for the selected period.
- Last close
- $0.77
- Period change
- -52.85%
- Period low
- $0.77
- Period high
- $1.64
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $0.8442 | $0.8921 | $0.76 | $0.7732 | 3.22M |
| Sep 15, 2026 | $1.02 | $1.03 | $0.83 | $0.8313 | 1.42M |
| Sep 14, 2026 | $1.03 | $1.06 | $0.99 | $0.9994 | 555.26K |
| Sep 11, 2026 | $1.16 | $1.16 | $1.02 | $1.04 | 1.88M |
| Sep 10, 2026 | $1.20 | $1.21 | $1.115 | $1.14 | 600.85K |
| Sep 9, 2026 | $1.26 | $1.265 | $1.19 | $1.20 | 586.95K |
| Sep 8, 2026 | $1.29 | $1.34 | $1.24 | $1.25 | 757.24K |
| Sep 4, 2026 | $1.35 | $1.36 | $1.29 | $1.31 | 549.21K |
| Sep 3, 2026 | $1.39 | $1.39 | $1.34 | $1.35 | 386.04K |
| Sep 2, 2026 | $1.35 | $1.41 | $1.345 | $1.38 | 532.23K |
| Sep 1, 2026 | $1.33 | $1.36 | $1.31 | $1.33 | 532.62K |
| Aug 31, 2026 | $1.40 | $1.445 | $1.32 | $1.33 | 633.1K |
| Aug 28, 2026 | $1.50 | $1.51 | $1.38 | $1.39 | 696.29K |
| Aug 27, 2026 | $1.55 | $1.575 | $1.48 | $1.48 | 534.04K |
| Aug 26, 2026 | $1.50 | $1.57 | $1.46 | $1.56 | 536.19K |
| Aug 25, 2026 | $1.53 | $1.57 | $1.48 | $1.50 | 475.57K |
| Aug 24, 2026 | $1.58 | $1.65 | $1.51 | $1.525 | 1.16M |
| Aug 21, 2026 | $1.51 | $1.64 | $1.51 | $1.63 | 499.11K |
| Aug 20, 2026 | $1.61 | $1.63 | $1.475 | $1.515 | 1.49M |
| Aug 19, 2026 | $1.65 | $1.71 | $1.615 | $1.64 | 716.17K |
Latest NMRA news
The latest Smart Investors Daily articles mentioning NMRA.
Stock researchCompany · Earnings
Loading stock research…